Melanoma/Skin Cancer News

Expanded use of chimeric antigen receptor T cells for cancer treatment requires that less expensive therapies be developed faster using multiple manufacturing models, according to an FDA official.

Patients with AKI may continue treatment with immune checkpoint inhibitors, even if they have experienced immune checkpoint inhibitor-AKI, according to data published in the Journal for ImmunoTherapy of Cancer.

The FDA granted fast track designation to UV1 in combination with checkpoint inhibitor therapy for treatment of unresectable or metastatic melanoma.

A personalized approach to radiation therapy can maximize therapeutic effect across multiple cancer types, according to findings published in The Lancet Oncology.

Reduction in circulating tumor DNA appeared correlated with longer OS among patients with previously treated metastatic uveal melanoma who received tebentafusp, according to study results presented at the virtual ESMO Congress.

American Association for Cancer Research unveiled its annual cancer progress report today, outlining advancements in the past year and highlighting breakthroughs in research since the signing of the National Cancer Act 50 years ago.

Indications for which cancer drugs receive accelerated approval often remain on drug labeling after confirmatory trials show no improvement in the primary efficacy endpoint, results of a retrospective, observational study showed.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

Surgical delays of 1 year or less were associated with tumor growth in a cohort of patients with squamous cell carcinomas, according to a study.